Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Louis Keppler

Orthopaedic Surgery Mayfield Heights, OH Medical Doctor

NPI 1235108119 CMS profile 191494

300 Allen Bradley Dr Ste 200, Mayfield Heights, OH 44124

Open in the dashboard

General payments

$173,495

110 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$79,744

4 holdings reported · through program year 2025

Through program year 2025, Louis Keppler of Mayfield Heights, OH is reported in the CMS Open Payments database as having received $173,495 across 110 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $79,744 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $63 4
2024 General $454 17
2023 General $1,480 22
2022 General $743 17
2021 General $1,537 16
2020 General $152,633 10
2019 General $16,584 24
2022 Ownership $15,000 1
2021 Ownership $15,000 1
2020 Ownership $15,000 1
2019 Ownership $34,744 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Louis Keppler
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Louis Keppler were reported at $63. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Louis Keppler Orthopaedic Surgery median Middle half National median
2019 $16,584 $644 $140–$2,844 $163
2020 $152,633 $312 $75–$1,860 $114
2021 $1,537 $520 $117–$2,495 $132
2022 $743 $598 $128–$2,731 $149
2023 $1,480 $461 $128–$2,264 $160
2024 $454 $497 $134–$2,475 $164
2025 $63 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. WishBone Medical Inc. $148,089 2 payments
  2. Medacta USA, Inc. $13,714 6 payments
  3. Back 2 Basics Direct, LLC $4,412 2 payments
  4. Arteriocyte Medical Systems, Inc. $3,035 5 payments
  5. Arthrex, Inc. $1,216 2 payments
  6. Aesculap Implant Systems, LLC $1,161 7 payments
  7. Horizon Therapeutics plc $462 26 payments
  8. Medtronic, Inc. $192 4 payments
  9. AbbVie, Inc. $189 10 payments
  10. Orthofix Medical, Inc. $164 3 payments
  11. Other $861 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Current or prospective ownership or investment interest $148,089 2 payments
  2. Travel and Lodging $18,720 9 payments
  3. Food and Beverage $2,962 95 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,500 1 payment
  5. Education $1,224 3 payments
Products named General payments · program years 2019–2025
  1. GMK SPHERE $8,596 3 payments
  2. MYSPINE $4,984 2 payments
  3. ACTIVL $1,161 7 payments
  4. Magellan $390 3 payments
  5. AMISTEM $303 3 payments
  6. PENNSAID $194 13 payments
  7. INTELLIS ADAPTIVESTIM $192 4 payments
  8. M6-C $139 1 payment
  9. DUEXIS $122 9 payments
  10. VRAYLAR $121 6 payments
  11. Other $1,192 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

457

Median for Orthopedic Surgery: 203

Drug cost

$7,306

Median for Orthopedic Surgery: $1,433

Branded share of claims

40.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 14 $3,500
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 126 $2,148
Celecoxib Generic 12 $371
Methylprednisolone Generic 43 $276
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 32 $256
Oxycodone Hcl Generic 24 $214
Tramadol Hcl Generic 45 $164
Morphine Sulfate Er Morphine Sulfate Brand 12 $107
Gabapentin Generic 26 $107
Cephalexin Generic 20 $55

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$252,360

Of which drugs: $8,837

Medicare patients

420

Average age 74

Services billed

9,860

199 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 28%
Diabetes 24%
Depression 21%
Chronic kidney disease 19%
Cancer 18%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 21 66 $3,394
Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg J7328 Office 11 6,558 $2,947
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 102 594 $429
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 100 570 $48

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $98
$98 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $26
  • Lundbeck LLC $25
$52 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $35
$35 — —
SPINRAZA
  • Biogen, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record